DeepMind's new deep learning model lands in Nature, Big Pharma's $18B+ plans for China, FDA clears first epigenetic reprogramming trial
Weekly Tech+Bio Highlights #71: More China…
DeepMind's new deep learning model lands in Nature, Big Pharma's $18B+ plans for China, FDA clears first epigenetic reprogramming trial